Charles Schwab’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Charles Schwab’s Portfolio FRTX Stock Details FRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-11	Closed	-$14K	–	3147
2016 Q1	$14K	Hold	11	–	–	﹤0.01%	3049
2015 Q4	$15K	Hold	11	–	–	﹤0.01%	3091
2015 Q3	$16K	Hold	11	–	–	﹤0.01%	3082
2015 Q2	$25K	Hold	11	–	–	﹤0.01%	3081
2015 Q1	$33K	Hold	11	–	–	﹤0.01%	3066
2014 Q4	$37K	Hold	11	–	–	﹤0.01%	3094
2014 Q3	$39K	Hold	11	–	–	﹤0.01%	3058
2014 Q2	$42K	Sell	11 -36	-77%	-$135K	﹤0.01%	3071
2014 Q1	$191K	Hold	47	–	–	﹤0.01%	2954
2013 Q4	$175K	Hold	47	–	–	﹤0.01%	2984
2013 Q3	$190K	Sell	47 -14	-23%	-$105K	﹤0.01%	2935
2013 Q2	$624K	Buy	+61	New	+$676K	﹤0.01%	2411

Other funds holding FRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CAM

ClariVest Asset Management San Diego, California $980M AUM 60.89% 1-Year Est. Return

EGA

Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return

Charles Schwab's FRTX Position: Q2 2016 in Review

Charles Schwab sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q2 2016, closing a stake of 11 shares — an estimated $14K sold.

Charles Schwab first reported a position in FRTX in Q2 2013 and held it in 12 quarters. The position peaked at $624K in Q2 2013. 36 funds tracked by Wall St. Rank hold FRTX as of Q2 2016.

Charles Schwab reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Charles Schwab sold 11 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $14K.
Charles Schwab first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
Charles Schwab's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $624K in Q2 2013.
36 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Charles Schwab's 13F filing for Q2 2016, filed 15 Aug 2016.